AKT1 and non-small cell lung carcinoma: A phase II study showed that the combination of the AKT inhibitor MK-2206 with erlotinib in patients with advanced EGFR-mutated NSCLC who previously progressed during treatment with erlotinib showed an ORR of 9% and a PFS of 4.4 months [93].